US children's hospital research bolsters case for flu vaccines

13 November 2006

Going into another flu season, a new study reports that hospitalizing children for influenza may cost up to three or four times the previously-accepted estimates. Pediatric researchers from the Children's Hospital of Philadelphia say their finding strengthens the economic justification for broadly vaccinating children against flu. The study appears in the November issue of Pediatrics.

"We found the cost of influenza-related hospitalizations in children was about $13,000 each - compared to most prior studies that estimated the cost at $3,000-$4,000," said study leader Ron Keren, a pediatrician at the hospital. "This suggests that annual influenza vaccinations for children, especially for those with certain high-risk conditions, may be more cost-effective than previously thought," he added.

The researchers analyzed billing data for 727 patients up to age 21 who were admitted to the hospital with laboratory-confirmed influenza over four consecutive flu seasons, from 2000 to 2004. The study team statistically adjusted the direct medical costs to account for geographic variations in these.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight